Best Weight Loss Medication: An Evidence-Based Comparison

This article is for education only and does not constitute medical advice. It is not a substitute for professional evaluation by a licensed clinician. Weight-loss medications are prescription drugs with real indications, contraindications, and monitoring requirements. Do not start, stop, or change any medication on your own; decisions about weight management pharmacotherapy belong with a licensed prescriber who knows your medical history. Individual results vary, and no specific outcomes are guaranteed.

---

The question "what is the best weight loss medication?" has a boring answer: it depends on who is asking. Not in a hedge-everything way — in the specific way that five drug classes with five different evidence profiles, five different side-effect signatures, and five different candidate populations cannot collapse into one ranking without losing the information that actually matters.

This article lays out the current landscape of prescription weight-loss medications as of September 2026 — what the strongest evidence shows for each class, what the typical effect size looks like in trials, and who each one tends to fit. It is not a personal recommendation. It is a map of the territory.

One framing note before the list: "best" in obesity pharmacotherapy is not a synonym for "strongest average effect." A medication that produces larger average weight reduction is not automatically the right medication for a person whose comorbidities, contraindications, insurance coverage, tolerability, or preferences point somewhere else. Clinical guidelines from the American Association of Clinical Endocrinology and the Obesity Society emphasize individualized selection over any universal first choice.¹⁰

---

The Weight Loss Medication Landscape at a Glance

Five prescription classes are currently used for weight management in the United States, plus metformin, which occupies an honest gray zone as an off-label option. They are grouped below by evidence tier, not by marketing volume.

Class	Representative drugs	Evidence tier	Approx. mean weight loss in trials	First-line?
GLP-1 / GIP receptor agonists	Semaglutide, tirzepatide, liraglutide	Strongest — multiple large Phase 3 RCTs + CV outcomes data	8% (liraglutide) to 22% (tirzepatide)	Yes, for most candidates
Phentermine/topiramate ER	Qsymia	Strong — Phase 3 RCTs + diabetes prevention data	~10% at the approved maintenance dose	Yes, selected candidates
Naltrexone/bupropion ER	Contrave	Moderate — Phase 3 RCTs, smaller effects	~5–6% at one year	Yes, selected candidates
Orlistat	Xenical, Alli	Established — older, smaller effects	~3–5%	Third-line in most guidelines
Metformin (off-label)	Glucophage and generics	Moderate — strongest signal in insulin resistance / PCOS	2–4% (variable)	Not indicated for weight loss alone

The table is a starting orientation. The sections below unpack what the numbers actually mean — and what they do not.

---

GLP-1 and GIP Receptor Agonists: The Deepest Evidence Base

GLP-1 receptor agonists are incretin mimetics: they mimic glucagon-like peptide-1, a gut hormone released after eating. GLP-1 receptor activation slows gastric emptying, increases satiety, reduces appetite, and improves glucose regulation. Tirzepatide adds a GIP (glucose-dependent insulinotropic polypeptide) receptor component, making it a dual agonist. These mechanisms are why the class dominates current obesity pharmacotherapy — and why the class also carries a distinct side-effect profile dominated by gastrointestinal effects.

Semaglutide (Wegovy)

Semaglutide is the GLP-1 receptor agonist with the largest cumulative evidence base in obesity. The STEP (Semaglutide Treatment Effect in People with Obesity) trial program established its efficacy across populations with and without type 2 diabetes:

• STEP 1 — in adults with overweight or obesity without diabetes, once-weekly semaglutide 2.4 mg produced a mean weight reduction of roughly 15% at 68 weeks versus about 2.4% with placebo plus lifestyle intervention.¹
• STEP 2 — in adults with overweight or obesity and type 2 diabetes, the effect was smaller (approximately 10%) — an important nuance, because the presence of diabetes attenuates weight response across every medication class.²
• STEP 5 — two-year data confirmed durability: participants on semaglutide continued to lose or maintain through 104 weeks.³
• STEP 4 — withdrawal data clarified what happens when the drug stops: participants who switched to placebo regained a substantial fraction of lost weight within a year, while those who continued semaglutide maintained or extended losses.⁴
• STEP 8 — a head-to-head trial against daily liraglutide 3.0 mg found semaglutide produced roughly twice the weight reduction, establishing a within-class hierarchy.⁵
• SELECT — the cardiovascular outcomes trial in adults with obesity and established cardiovascular disease but no diabetes: semaglutide reduced major adverse cardiovascular events by approximately 20% over a mean follow-up of roughly 40 months.⁶ This matters beyond efficacy — it is outcomes data, not surrogate data.

The step-1 extension trial added the compliance-relevant caveat: after stopping semaglutide, participants regained about two-thirds of lost weight within a year, with cardiometabolic improvements reverting toward baseline.⁷ Long-term use is not a failure of the drug; it is the design of the therapy.

Who it tends to fit: adults with obesity or overweight plus at least one weight-related comorbidity, people with cardiovascular disease who also carry excess weight, and those who prefer once-weekly dosing. Common reasons it does not fit: history of medullary thyroid carcinoma or MEN2, personal or family history of pancreatitis, current pregnancy, severe gastroparesis, and concurrent use of other GLP-1 products.

Tirzepatide (Zepbound)

Tirzepatide is a dual GIP/GLP-1 receptor agonist. The SURMOUNT program is its evidence spine:

• SURMOUNT-1 — in adults with obesity or overweight without diabetes, the highest studied dose produced a mean weight reduction of approximately 21–22% at 72 weeks, the largest effect size observed in any published obesity pharmacotherapy trial to date.⁸
• SURMOUNT-4 — randomized withdrawal confirmed the same pattern as STEP 4: stopping tirzepatide leads to substantial regain; continuing maintains the effect.⁹
• SURMOUNT-3 and related trials established efficacy in populations with comorbid type 2 diabetes and in Chinese adults with obesity (SURMOUNT-CN), supporting cross-population generalizability.⁸
• A 2025 head-to-head trial comparing tirzepatide directly with semaglutide for obesity found tirzepatide produced greater mean weight reduction — the first large randomized comparison between the two leading agents.¹¹

The tolerability profile is similar to semaglutide's — nausea, diarrhea, constipation, vomiting — and tends to be front-loaded during dose escalation.

Who it tends to fit: adults with obesity or overweight plus comorbidity who want the largest evidence-backed effect size and accept once-weekly injectable dosing. The same class-level contraindications (thyroid C-cell tumor history, pancreatitis history, pregnancy, gastroparesis) apply.

Liraglutide (Saxenda)

Liraglutide 3.0 mg is the older, daily-dosed GLP-1 receptor agonist, approved for weight management since 2014. The SCALE program established its efficacy:

• SCALE Obesity and Prediabetes — a 56-week trial in adults with overweight or obesity: mean weight loss of approximately 8% with liraglutide versus about 2.6% with placebo.¹²
• SCALE Maintenance — after low-calorie diet-induced weight loss, liraglutide produced additional loss and better maintenance versus placebo.¹³
• SCALE Sleep Apnea — liraglutide reduced weight and improved apnea-hypopnea index in participants with obesity and moderate-to-severe obstructive sleep apnea.¹⁴
• SCALE Diabetes — in participants with type 2 diabetes, efficacy was attenuated (roughly 6% versus 2% with placebo) — the same diabetes-attenuation pattern seen with semaglutide.¹⁵

Who it tends to fit: adults who prefer or tolerate daily dosing, those for whom payor coverage favors the older agent, and adolescents (liraglutide carries a pediatric obesity indication that semaglutide and tirzepatide do not uniformly share). The STEP 8 head-to-head data, however, mean liraglutide is no longer the default GLP-1 choice when coverage allows newer agents.⁵

Choosing within the GLP-1 class

The intra-class decision — semaglutide versus tirzepatide versus liraglutide — depends on coverage, comorbidity profile, dosing preference, and tolerability. Our dedicated guide to which GLP-1 is best for weight loss walks through the decision framework in depth, and our GLP-1 weight-loss comparison covers the class-level evidence in more detail. If you are currently on one and considering a change, our guide to switching from semaglutide to tirzepatide covers the practical transition questions.

For patients in the Dallas–Fort Worth area evaluating a GLP-1 program, the same evidence applies — the geography changes the delivery model, not the pharmacology.

---

Phentermine/Topiramate Extended-Release (Qsymia)

Phentermine/topiramate ER combines a sympathomimetic appetite suppressant (phentermine, approved for short-term weight loss since 1959) with an anticonvulsant (topiramate) in a single extended-release capsule. The combination was approved for chronic weight management in 2012.

The Phase 3 evidence base:

• EQUIP — in adults with obesity (Class II and above), the top dose produced a mean weight loss of approximately 10.9% at 56 weeks versus 1.6% with placebo.¹⁶
• CONQUER — in adults with overweight or obesity plus at least two weight-related comorbidities, the two approved maintenance doses produced mean losses of roughly 8–10% versus about 1.5% with placebo.¹⁷
• Pooled analyses found that the degree of weight loss predicted diabetes prevention in prediabetic participants — a meaningful outcomes signal for the right population.¹⁸

Who it tends to fit: adults with obesity who cannot access or tolerate GLP-1-class medications, and those whose payor coverage favors older agents. Key contraindications include pregnancy (topiramate teratogenicity — the REMS program requires contraception counseling and monthly pregnancy testing for women of childbearing potential), glaucoma, hyperthyroidism, recent MAOI use, and uncontrolled hypertension. Cognitive side effects (word-finding difficulty, paresthesias) are class-specific and dose-dependent.

---

Naltrexone/Bupropion Extended-Release (Contrave)

Naltrexone/bupropion ER combines an opioid antagonist with an aminoketone antidepressant. The mechanistic rationale targets central appetite and reward pathways rather than peripheral incretin signaling.

The Phase 3 evidence base:

• COR-I — in overweight and obese adults, the combination produced approximately 6.1% mean weight loss at 56 weeks versus about 1.3% with placebo.¹⁹
• COR-Diabetes — in participants with type 2 diabetes, effects were attenuated (roughly 5% versus 1.8%), consistent with the diabetes pattern across all classes.²⁰
• Longer-term analyses found that early weight loss predicts sustained response — a useful clinical signal for shared decision-making about whether to continue.²¹

Who it tends to fit: adults whose eating behavior has a strong reward-driven component (the medication is sometimes preferred for binge-eating patterns), and those who cannot use GLP-1-class agents. Key contraindications include uncontrolled hypertension, seizure history, current or recent opioid use (naltrexone blocks opioid analgesics), chronic opioid therapy, eating disorders, and concurrent MAOI use. The bupropion component carries the same suicidality-class warning as all antidepressants. For a deeper look at bupropion's weight evidence outside the combination product, see our Wellbutrin for weight loss guide.

---

Orlistat (Xenical, Alli)

Orlistat is a lipase inhibitor: it blocks absorption of roughly 30% of dietary fat in the gut, which reduces caloric uptake mechanically rather than acting on appetite or reward pathways. It is the oldest agent on this list — approved in 1999 — and its evidence base reflects that era.

• XENDOS — a four-year randomized trial in obese adults found that orlistat plus lifestyle intervention produced approximately 6% mean weight loss at one year (versus about 4% with lifestyle alone) and reduced the incidence of type 2 diabetes in participants with impaired glucose tolerance.²²
• Effect sizes in more recent meta-analyses are smaller than in the GLP-1 era — typically 3–5% at one year.

The side-effect profile is predictable and mechanical: oily stool, fecal urgency, and fat-soluble vitamin malabsorption. These effects are directly tied to dietary fat intake, which is both the mechanism and the adherence challenge.

Who it tends to fit: adults who prefer an oral, non-systemic mechanism, cannot access other agents, or need a low-cost option. Orlistat is available over-the-counter at half the prescription dose (Alli). Most contemporary guidelines place it third-line behind GLP-1-class agents and the two combination oral agents.

---

Metformin: The Off-Label Honest Gray Zone

Metformin is not approved for weight loss, and the evidence reflects that status. Its effect on weight is modest and variable — typically 2–4% in the general population, larger and more consistent in people with insulin resistance or polycystic ovary syndrome (PCOS).²³

Metformin's real role in weight management is as an adjunct: it improves insulin sensitivity, modestly reduces weight in insulin-resistant states, and carries decades of safety and cardiovascular outcomes data in diabetes. It is cheap, oral, and well tolerated by most people (gastrointestinal side effects are common but usually transient).

What metformin is not: a weight-loss drug. If someone has insulin resistance, prediabetes, or PCOS, metformin may be a reasonable part of a medical plan. If someone is asking "what is the best weight loss medication," metformin is not the answer to that question. Our metformin for weight loss guide covers the evidence in more depth, including the insulin-resistant populations where it is most defensible.

---

What About Supplements?

Supplements occupy a different regulatory and evidentiary category than everything above. No supplement is FDA-approved as a weight-loss medication, and no supplement has produced trial effect sizes comparable to any prescription agent on this list. If you are comparing the supplement lane to the prescription lane, our best GLP-1 supplement for weight loss guide lays out the evidence tiers honestly — including where they fall short. Berberine, the most-searched "natural" option, has real but modest evidence in insulin-resistant populations; our berberine for weight loss guide covers it in depth.

---

The Practical Decision Framework

Given the evidence above, the actual clinical decision usually follows this sequence:

1. Is the person a pharmacotherapy candidate at all? Current guidelines generally support medication for adults with BMI ≥ 30, or BMI ≥ 27 plus at least one weight-related comorbidity, alongside lifestyle intervention — not instead of it.¹⁰
2. What comorbidities shape the choice? Cardiovascular disease favors semaglutide (SELECT data).⁶ Obstructive sleep apnea may favor liraglutide or tirzepatide (both have positive trial data in this population).¹⁴ Binge-eating patterns may favor naltrexone/bupropion.²⁴ Insulin resistance or PCOS may bring metformin into the plan as an adjunct.
3. What does coverage allow? Real-world access still shapes prescribing patterns. Real-world evidence from 2025 confirms that GLP-1-class medications dominate newer prescriptions but discontinuation rates remain substantial.²⁵
4. What is the person's tolerability and preference profile? Daily versus weekly dosing, injection versus oral, GI side-effect tolerance, and cognitive side-effect tolerance all matter and are person-specific.
5. What is the maintenance plan? Every major trial with a withdrawal arm shows the same pattern: stopping the medication leads to substantial regain.⁴⁷⁹ A medication is not a course of treatment with an end date; it is a chronic therapy. This is not a reason not to start — it is a reason to start with eyes open.

One practical note for patients with any procedure on the calendar: GLP-1-class medications affect gastric emptying, which has real perioperative implications. Our GLP-1 perioperative safety guide covers the conversation to have with your surgical team before any procedure requiring anesthesia.

---

FAQ

What is the best weight loss medication overall?

There is no single "best" — the right medication depends on your medical history, comorbidities, coverage, and preferences. That said, GLP-1 receptor agonists currently carry the strongest evidence base, with tirzepatide producing the largest mean weight reduction in trials (approximately 21–22%) and semaglutide carrying the broadest outcomes data, including a cardiovascular benefit in people with obesity and established heart disease.⁶⁸ Liraglutide is effective but produces smaller effects than the newer agents.⁵

How much weight can you lose on weight-loss medication?

Trial averages range from roughly 3% with orlistat to approximately 22% with the highest tirzepatide dose.⁸²² These are means — individual responses vary substantially, and the diabetes-attenuation pattern means people with type 2 diabetes typically see smaller effects than people without diabetes across every class.²¹⁵²⁰ No specific outcome can be promised for any individual.

What happens if you stop taking a weight-loss medication?

The withdrawal data is consistent across classes: substantial regain. In the STEP 1 extension, participants who stopped semaglutide regained about two-thirds of lost weight within a year.⁷ SURMOUNT-4 found the same pattern with tirzepatide.⁹ These medications are chronic therapies, not short courses. Deciding whether and when to discontinue is a conversation with your prescriber, not a unilateral decision.

Is tirzepatide better than semaglutide?

In the 2025 head-to-head SURMOUNT-5 trial, tirzepatide produced greater mean weight reduction than semaglutide in adults with obesity.¹¹ Whether that makes it "better" for a specific person depends on coverage, tolerability, comorbidity profile, and preference. Both are once-weekly injectable medications in the same broad class with similar GI side-effect profiles.

Are weight-loss medications safe?

Every medication on this list has an FDA-approved indication for weight management (except metformin, which is used off-label) and a characterized safety profile established in large trials. None are risk-free. GLP-1-class agents carry thyroid C-cell tumor warnings, pancreatitis precautions, and gastrointestinal side effects. Phentermine/topiramate carries teratogenicity warnings and requires contraception in women of childbearing potential. Naltrexone/bupropion is contraindicated with opioids and seizure disorders. Orlistat's side effects are mechanical and dietary-fat-dependent. All decisions require a licensed prescriber who knows your history.

What about over-the-counter weight-loss pills?

The only FDA-recognized OTC weight-loss agent is Alli (orlistat 60 mg), which is half the prescription dose. No supplement is FDA-approved as a weight-loss medication, and no supplement has produced trial evidence comparable to any prescription agent on this list. Supplements are regulated under DSHEA, which does not require pre-market efficacy or safety evidence.

---

Related Reading

• Which GLP-1 Is Best for Weight Loss? — the intra-class decision framework
• GLP-1 Weight-Loss Comparison — class-level evidence deep dive
• Switching From Semaglutide to Tirzepatide — the practical transition guide
• GLP-1 Perioperative Safety Guide — what to tell your surgical team
• Metformin for Weight Loss — the off-label evidence
• Berberine for Weight Loss — the supplement-lane evidence
• Wellbutrin for Weight Loss — the bupropion evidence in context

---

Sources

---

---

LuxeFit Wellness is a cash-pay wellness clinic serving the Dallas–Fort Worth area and patients nationwide through telemedicine. This content is educational only and does not constitute medical advice. It does not recommend, endorse, or evaluate any specific medication product, brand, or dosing regimen, and it does not provide pricing or sourcing guidance. Decisions about weight-loss medications belong with a licensed prescriber who knows your medical history.

You built it. We optimize it.